History-informed perspectives on the modeling and simulation of therapeutic drug actions

Simulation for Designing Clinical Trials: A Pharmacokinetic-Pharmacodynamic Modeling Perspective

Volumn , Issue , 2002, Pages 245-270

  Urquhart, John ^a,b,c  

^a AARDEX Group   (Switzerland)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84855887242     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (51)

1. WB Cannon. The Wisdom of the Body. New York: W. W. Norton, 1939.
2. C Bernard. Introduction a l’Etude de la Médecine Experimentale. Paris: Balliere, 1865.
3. E Koch. Die Reflektorische Selbststeuerung des Kreislaufes. Dresden: Steinkopff, 1931.
4. JJ Lamberti, Jr, J Urquhart, RD Siewers. Observations on the regulation of arterial blood pressure in unanesthetized dogs. Circulation Research 23:415-428, 1968.
5. N Minorsky. Directional stability of automatically steered bodies. J Amer Soc Naval Engineers 42:280-309, 1922.
6. H Nyquist. Regeneration theory. Bell Syst Tech J 11:126-147, 1932.
7. JC Maxwell. On governors. Proc Roy Soc London 16:270-283, 1868.
8. J Urquhart, FE Yates, AL Herbst. Hepatic regulation of adrenal cortical function. Endocrinology 64:816-830, 1959.
9. FE Yates, J Urquhart. Control of plasma concentrations of adrenocortical hormones. Physiol Rev 42:359-443, 1962.
10. J Urquhart. Blood-borne signals—the measuring and modelling of humoral communication and control: 14th Bowditch Lecture of the American Physiological Society. The Physiologist 13(1):7-41, 1970.
11. MF Dallman, FE Yates. Dynamic asymmetries in the coricosteroid feedback path and distribution-metabolism-binding elements of the adrenocortical system. Ann NY Acad Sci 156(2):696-721, 1969.
12. FE Yates, RD Brennan, J Urquhart. Application of control systems theory to physiology. Adrenal glucocorticoid control system. Fed Proc 28:71-83, 1969.
13. RN Bergman, J Urquhart. Pilot gland approach to the study of insulin secretory dynamics. Rec Progr Hormone Res 27:583-605, 1971.
14. RN Bergman. Toward physiological understanding of glucose tolerance: minimalmodel approach. Diabetes 38:1512-1527, 1989.
15. FS Grodins. Control Theory and Biological Systems. New York: Columbia University Press, 1963.
16. AC Guyton, TG Coleman, HJ Granger. Circulation: overall regulation. Ann Revs Physiology Palo Alto: Annual Reviews, 1972, pp 13-44.
17. http://www.biosim.com
18. AC Guyton. Blood pressure control—special role of the kidneys and body fluids. Science 252:1813-1816, 1991.
19. L Stark. Stability, oscillation, and noise in the human pupil servomechanism. Prof Inst Radio Engr 47:1925-1939, 1959.
20. M Clynes. Unidirectional rate sensitivity: a biocybernetic law of reflex and humoral systems as physiologic channels of control and communication. Ann NY Acad Sci 92:946-969, 1962.
21. M Clynes. The non-linear biological dynamics of unidirectional rate sensitivity illustrated by analog computer analysis, pupillary reflex to light and sound, and heart rate behavior. Ann NY Acad Sci 98:806-845, 1962.
22. DW Bronk, G Stella. The response to steady pressures of single end organs in the isolated carotid sinus. Am J Physiol 110:708-714, 1935.
23. S Landgren. On the excitation mechanism of the carotid baroreceptors. Acta Physiol Scand 26:1-34, 1952.
24. WR Loewenstein. Rate sensitivity of a biological transducer. Ann NY Acad Sci 156(2):892-900, 1969.
25. JC Houk. Rate sensitivity of mechanoreceptors. Ann NY Acad Sci 156(2):901-916, 1969.
26. CH Kleinbloesem, P van Brummelen, M Danhof, H Faber, J Urquhart, DD Breimer. Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans. Clin Pharmacol Ther 41:26-30, 1987.
27. DD Breimer, J Urquhart. Nifedipine GITS. Lancet 341:306, 1993.
28. J Urquhart. Controlled drug delivery: pharmacologic and therapeutic aspects. J Internal Med 248:357-376, 2000.
29. PROCARDIA-XL (nifedipine) Extended Release Tablets for Oral Use. Physicians’ Desk Reference, 55th ed. Montvale (NJ): 2001, pp 2512-2514.
30. PROCARDIA nifedipine CAPSULES for Oral Use. Physicians’ Desk Reference, 55th ed. Montvale (NJ): 2001, pp 2510-2512.
31. MC Houston, R Hodge. Beta-adrenergic blocker withdrawal syndromes in hypertension and other cardiovascular diseases. Am Heart J 116:515-523, 1988.
32. DM Gilligan, WL Chan, R Stewart, CM Oakley. Adrenergic hypersensitivity after beta-blocker withdrawal in hypertrophic cardiomyopathy. Am J Cardiol 68:766-772, 1991.
33. Anon. Long-term use of beta blockers: the need for sustained compliance. WHO Drug Information 4(2):52-53, 1990.
34. A Cleton, D Mazee, RA Voskuyl, M Danhof. Rate of change of blood concentrations is a major determinant of the pharmacodynamics of midazolam in rats. Br J Pharmacol 127:227-235, 1999.
35. JA Cramer. Microelectronic systems for monitoring and enhancing patient compliance with medication regimens. Drugs 49:321-327, 1995.
36. H Kastrissios, TF Blaschke. Medication compliance as a feature in drug development. Ann Rev Pharmacol Toxicol 37:451-475, 1997.
37. J Urquhart. The electronic medication event monitor—lessons for pharmacotherapy. Clin Pharmacokinet 32:345-356, 1997.
38. CARDURA (doxazosin mesylate) tablets. Physicians’ Desk Reference, 55th ed. Montvale (NJ): 2001, pp 2473-2477.
39. PRILOSEC (omeprazole) DELAYED-RELEASE CAPSULES, Physicians’ Desk Reference, 55th ed. Montvale (NJ): 2001, pp 587-591.
40. PAXIL brand of paroxetine hydrochloride tablets and oral suspension, Physicians’ Desk Reference, 55th ed. Montvale (NJ): 2001, pp 3114-3120.
41. JF Rosenbaum, M Fava, SL Hoog, RC Ascroft, WB Krebs. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 44:77-87, 1998.
42. HAJ Struyker-Boudier. Dynamic systems analysis as a basis for drug design: application to antihypertensive drug action. In: EJ Ariens, ed. Drug Design, vol 10. New York: Academic Press, 1980, pp 145-191.
43. HAJ Struyker-Boudier. Kinetics and dynamics of cardiovascular drug action: introduction. In CJ Boxtel, NHG Holford, M Danhof, eds. The In Vivo Study of Drug Action. Amsterdam: Elsevier, 1992, pp 219-231.
44. JG Harter, CC Peck. Chronobiology: suggestions for integrating it into drug development. Ann NY Acad Sci 618:563-571, 1991.
45. J Urquhart. Pharmacodynamics of variable patient compliance: implications for pharmaceutical value. Adv Drug Delivery Revs 33:207-19, 1998.
46. J Urquhart. Physiological actions of adrenocorticotropic hormone. In: E Knobil, WH Sawyer, eds. The Pituitary Gland and Its Neuroendocrine Control, part 2. Washington DC: American Physiology Society, 1974, chap 27, pp 133-157 (Handbook of Physiology, Endocrinology, sec 7, vol 4).
47. A Fauci. Research sheds light on treatment interruption. AIDS Alert 16:114-146, 2001.
48. B Uvnas. From physiologist to pharmacologist—promotion or degradation? Fifty years in retrospect. Ann Rev Pharmacol Toxicol 24:1-18, 1984.
49. J Urquhart. Can drug delivery systems deliver value in the new pharmaceutical marketplace? Brit J Clin Pharmacol 44:413-419, 1997.
50. E Knobil. The discovery of the hypothalamic gonadotropin-releasing hormone pulse generator and of its physiological significance. Endocrinology 131:1005, 1992.
51. A Dokoumetzidis, A Iliadis, P Macheras. Nonlinear dynamics and chaos theory: concepts and applications relevant to pharmacodynamics. Pharm Res 18:415-426, 2001.